ClinicalTrials.gg
CompletedNCT05097222Updated May 29, 2024

Impact of Photobiomodulation on Objective, Physiological Measures of Brain Function in Individuals With Post-Concussion Syndrome

An interventional study of BioFlex Dualport System and Sham device in Post-Concussive Syndrome, Chronic, Post-Concussion Syndrome and Mild Traumatic Brain Injury, sponsored by Dr George Medvedev. Completed at 2 sites in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Dr George Medvedev · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Post-Concussion Syndrome with a site in Canada — 3 open to participants now, 5 under way, none of them phase 3. Post-Concussion Syndrome · Canada.

Enrollment
24th of 30
19 · median 40
Started
2022
with 2 others
No phase
26 of 30
3 open now
Registered
24th of 30
by date
Lead sponsor
1 of 30
Dr George Medvedev

Among the 30 studies in Post-Concussion Syndrome with a site in Canada, this one is the 24th largest by enrollment, is one of 3 that started in 2022, is one of 26 with no phase, and was the 24th registered.

Post-Concussion Syndrome

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

Browse Post-Concussion Syndrome studies →

Open to participants now

3 of the 30 studies in Post-Concussion Syndrome with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Post-Concussion Syndrome with a site in Canada, or all of them as a file.
02

Study summary

Photobiomodulation therapy (PBMT) uses light to influence the mitochondria of cells. PBMT of the brain enhances the metabolic capacity of neurons and stimulates anti-inflammatory, anti-apoptotic, and antioxidant responses, as well as neurogenesis and synaptogenesis. Its therapeutic role in disorders such as dementia and Parkinson's disease, as well as to treat stroke, brain trauma, and depression has gained increasing interest.

BioFlex is a form of PBMT consisting of light-emitting diodes (LEDs) and laser diodes. BioFlex utilizes red and near infrared light which penetrates tissues up to a certain tissue depth and studies have shown stimulates tissue growth and repair at the cellular level. PBMT has been proven useful for the treatment of soft tissue pain. Several studies have shown benefit in using PBMT in the treatment of certain neurological conditions, including chronic, mild traumatic brain injury (mTBI).

The purpose of this exploratory investigation, therefore, is to examine efficacy of BioFlex laser therapy on measures of brain function in patients suffering from PCS after mild-moderate, closed-head, traumatic brain injury cases.

03

Conditions studied

  • Post-Concussive Syndrome, Chronic
  • Post-Concussion Syndrome
  • Mild Traumatic Brain Injury
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, at least 19 years of age or older
  2. Diagnosis of persistent post-concussional syndrome after ≥3 months of traumatic brain injury, based on the ICD-10 criteria. This diagnosis should be given to the patient from a clinical practitioner. ICD-10 clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol.
  3. Current pharmacologic management can remain stable throughout the protocol.
  4. Fluent in English
  5. Able to understand the form, study procedures and willing to participate in study.

Exclusion criteria

Exclusion Criteria:

  1. Malignant skin carcinoma within the treatment area (neck and cranium)
  2. Intake of photosensitizing medication.
  3. Prior history of PBMT therapy
  4. Current diagnosis of severe anxiety (or score of ≥15 on the GAD-7), severe depression (or score of ≥20 on the PHQ-9), schizophrenia or bipolar disorder
  5. History of other major neurological disorder (brain cancer, dementia, multiple sclerosis, stroke)
  6. Diagnosed epilepsy or history of seizures not effectively controlled by medications
  7. Exposed to an drug or device 30 days prior to starting the study, or concurrent use of an investigational drug or device while enrolled in the study
  8. Pregnant, suspected to be pregnant or planning to become pregnant during the study
  9. for the NeuroCatch® Platform 2, including:

9.1. Requires the use of hearing aids or a cochlear implant 9.2. Diagnosed with tinnitus that is currently active 9.3. Has temporary damage to hearing (e.g. punctured ear drum) 9.4. Unable to detect a 740Hz tone played at 85dB in both ears. 9.5. Implanted pacemaker or implanted electrical stimulators 9.6. Metal or plastic implants in the skull, excluding dental/facial implants 9.7. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 9.8. Previous exposure to the NeuroCatch® Platform 2 audio sequences in the last 3 months

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Active PBMT

    Participants will receive 50minutes of PBMT, three times a week, for 8 weeks.

    Device: BioFlex Dualport System

  • Sham comparator
    Sham PBMT

    Participants will receive 50minutes of Sham PBMT, three times a week, for 8 weeks. The Sham device will appear to function like the treatment device without providing any power intensity (0% power). At 0% power, no light is emitted from the LEDs.

    Device: Sham device

Interventions

  • DeviceBioFlex Dualport System

    The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.

    Also known as: Photobiomodulation

  • DeviceSham device

    Control

06

What researchers measure

Primary outcomes

  1. Response size of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2

    Event-related potentials (ERPs)

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

  2. Response timing of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2

    Event-related potentials (ERPs)

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

Secondary outcomes

  1. Number of adverse events

    Frequency and severity of adverse events

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

  2. Number of adverse device effects

    Frequency and severity of adverse device effects

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

  3. Pain Catastrophizing Scale Score

    Mean, standard deviation, and assessment of variance. It is a 13-item scale, with a total range of 0 to 52. Higher scores are associated with higher amounts of pain catastrophizing.

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

  4. Rivermead Post-Concussion Symptoms Questionnaire Score

    Mean, standard deviation, and assessment of variance. Scored on a scale of 0-64 where higher scores reflect greater severity of post concussive symptoms.

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

07

Study locations

2 sites
  • Center for Neurology Studies
    Surrey, British Columbia V3V 0C6, Canada
  • Meditech Rehabilitation Centre
    Etobicoke, Ontario M8W 4W3, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2023, 22 months.

Of 56 interventional studies with no phase under Post-Concussion Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 69. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Oct 28, 2021
StartActual
Jan 27, 2022
Primary completionActual
Dec 13, 2023
CompletionActual
Dec 13, 2023
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05097222
Lead sponsor
Dr George Medvedev
Collaborators
MediTech International Inc.
Responsible party
Dr George Medvedev (Sponsor-Investigator, HealthTech Connex Inc.) — Sponsor-investigator
First posted
Oct 28, 2021
Start date
Jan 27, 2022
Primary completion
Dec 13, 2023
Completion
Dec 13, 2023
Last update
May 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion